Positive findings from phase I trial of LY-353381 reported at ASCO meeting, lead to phase II study May 21, 1999 No Comments
First proteasome inhibitor in clinical development profiled at oncology meeting May 20, 1999 No Comments
Favorable pharmacokinetic, safety and efficacy profile for FMdC in phase I; phase II trials begin May 20, 1999 No Comments
Inhibitors of Ras prenylation with bicyclic structure designed at Merck & Co. May 20, 1999 No Comments
Cell Therapeutics initiates phase II trial of Apra; phase I results presented at ASCO May 20, 1999 No Comments
RSS